(193k) Investigating the Drug Delivery Effect for Anti-Cancer Compounds Using Graphene Oxide Nanoparticles

The application of nanoparticles in the drug delivery industry has always been of substantial importance for enhancing the delivery efficiency of drugs. As one of the most widely used materials among all the applied nanoparticles, superparamagnetic iron oxide (SPION) has shown a great range of medical applications such as magnetic resonance imaging (MRI) contrast agents and also drug delivery along with applications in tumor therapy and cardiovascular diseases. Furthermore, having remarkable interacting capabilities with blood proteins and cancer cells, SPION has proved to be one of the most promising drug carriers for cancer treatment. To be applicable, SPION should be attached to a biocompatible and water-soluble polymer compound, such as PEG/PLA in combination with graphene oxide. This delivery vehicle has been investigated using SEM, FTIR, and Raman spectroscopies. In addition, according to the calculated rate constants by the pseudo-first order kinetic model and pseudo-second order kinetic model, the drug loading time can decrease with an increase in drug concentration. In this project study, appropriate models for the drug absorption and desorption parameters have been investigated to better determine the range of application for this drug delivery method. The results demonstrate a drug delivery vehicle that is biocompatible with a high degree of water dispersity, owing to a superior delivery vector.

Furthermore, UV-Vis spectroscopy was used to determine adsorption and desorption isotherms for naphthol blue black dye, a drug surrogate, as well as bovine serum albumin (BSA) and doxorubicin hydrochloride (DOX) onto a graphene oxide layer. This study compares the relationship of drug size, adsorption/desorption isotherms, and kinetic models to drug delivery, particularly the average percentage cumulative drug release rate when subjected to various pH and buffered environments. The use of nanoparticles, both passive and active targeting strategies, to enhance intracellular concentrations of drugs in cancer cells while avoiding toxicity to normal cells will be detailed in this talk.